Chugai Pharmaceutical Co., Ltd. (OTCMKTS:CHGCY) Short Interest Up 1,500.0% in December

Chugai Pharmaceutical Co., Ltd. (OTCMKTS:CHGCYGet Free Report) saw a significant increase in short interest in the month of December. As of December 31st, there was short interest totalling 36,800 shares, an increase of 1,500.0% from the December 15th total of 2,300 shares. Based on an average daily volume of 214,500 shares, the short-interest ratio is currently 0.2 days.

Chugai Pharmaceutical Trading Up 1.9 %

Shares of Chugai Pharmaceutical stock opened at $21.48 on Wednesday. Chugai Pharmaceutical has a 12 month low of $14.52 and a 12 month high of $26.00. The firm has a market capitalization of $70.69 billion, a P/E ratio of 27.54 and a beta of 0.81. The business has a fifty day simple moving average of $21.96 and a two-hundred day simple moving average of $22.30.

About Chugai Pharmaceutical

(Get Free Report)

Chugai Pharmaceutical Co, Ltd., together with its subsidiaries, engages in the research, development, manufacture, sale, importation, and exportation of pharmaceuticals in Japan and internationally. The company’s products for oncology primarily include Avastin, FoundationOne, Polivy, Rozlytrek, Tecentriq, Perjeta, Alecensa, Herceptin, Kadcyla, Rituxan, and Gazyva; Edirol, an Osteoporosis agent; Mircera, an erythropoiesis agent; Oxarol, an agent for secondary hyperparathyroidism; and other diseases comprise Hemlibra, CellCept, Bonviva, Tamiflu, Evrysdi, Ronapreve, Vabysmo, and Enspryng.

Further Reading

Receive News & Ratings for Chugai Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chugai Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.